Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06380101 · ClinicalTrials.gov registry record · NA

Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)

A NA study of Rectal Cancer, sponsored by University of South Florida.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06380101: Recruiting NA study of Rectal Cancer, sponsored by University of South Florida.

NCT06380101 is a NA study of Rectal Cancer that is actively recruiting participants, run by University of South Florida. The registered enrollment target is 30 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06380101, a NA study of Rectal Cancer, is actively recruiting participants, sponsored by University of South Florida.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

Conditions Studied

Interventions

  • OTHER NEAAR Medical Food

Study Locations (1)

Florida

  • University of South Florida - Tampa

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2023-09-08
Est. Completion 2027-06
Phase NA
University of South Florida

252 total trials

What NCT06380101 shows while recruiting

NCT06380101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which NEAAR Medical Food is the first listed.

NCT06380101 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT06380101 about?

NCT06380101 is a clinical study titled "Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)". This clinical study aims to assess feasibility, safety, tolerability, and compliance of a Nonessential Amino Acid Restriction (NEAAR) medical food in adult patients with locally advanced rectal cancer during standard of care short course radiotherapy followed by standard of care chemotherapy.

What is the current status of trial NCT06380101?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2023-09-08. Estimated completion is 2027-06.

What conditions does trial NCT06380101 study?

This clinical trial studies the following conditions: Rectal Cancer.

What interventions are being tested in trial NCT06380101?

The interventions under investigation include: NEAAR Medical Food (OTHER).

Who is sponsoring clinical trial NCT06380101?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06380101 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Rectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06380101's enrollment target sits among peer trials

30 52nd of 70 higher than 16 of 70 other Rectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Rectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06380101, the US trial registry maintained by the National Library of Medicine. NCT06380101 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.